Pharsight

Diprivan patents expiration

DIPRIVAN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8476010 FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Dec, 2024

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5908869 FRESENIUS KABI USA Propofol compositions containing edetate
Mar, 2015

(9 years ago)

US5714520 FRESENIUS KABI USA Propofol compostion containing edetate
Mar, 2015

(9 years ago)

US5731355 FRESENIUS KABI USA Pharmaceutical compositions of propofol and edetate
Mar, 2015

(9 years ago)

US5731356 FRESENIUS KABI USA Pharmaceutical compositions of propofol and edetate
Mar, 2015

(9 years ago)

US5908869

(Pediatric)

FRESENIUS KABI USA Propofol compositions containing edetate
Sep, 2015

(8 years ago)

US5731355

(Pediatric)

FRESENIUS KABI USA Pharmaceutical compositions of propofol and edetate
Sep, 2015

(8 years ago)

US5714520

(Pediatric)

FRESENIUS KABI USA Propofol compostion containing edetate
Sep, 2015

(8 years ago)

US5731356

(Pediatric)

FRESENIUS KABI USA Pharmaceutical compositions of propofol and edetate
Sep, 2015

(8 years ago)

US8476010

(Pediatric)

FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Jun, 2025

(1 year, 2 days from now)

Diprivan is owned by Fresenius Kabi Usa.

Diprivan contains Propofol.

Diprivan has a total of 10 drug patents out of which 8 drug patents have expired.

Expired drug patents of Diprivan are:

  • US5908869
  • US5714520
  • US5731355
  • US5731356
  • US5908869*PED
  • US5731355*PED
  • US5714520*PED
  • US5731356*PED

Diprivan was authorised for market use on 02 October, 1989.

Diprivan is available in injectable;injection dosage forms.

Diprivan can be used as method for limiting the potential for microbial growth in the drug product, method of producing anesthesia, method of improving the time for administration or the time between changes of giving sets for the drug product.

The generics of Diprivan are possible to be released after 01 June, 2025.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using PROPOFOL ingredient

Market Authorisation Date: 02 October, 1989

Treatment: Method of improving the time for administration or the time between changes of giving sets for the drug product; Method of producing anesthesia; Method for limiting the potential for microbial growth ...

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DIPRIVAN before it's drug patent expiration?
More Information on Dosage

DIPRIVAN family patents

Family Patents